Technetium-99m macroaggregated albumin - BTG International
Alternative Names: 99mTc-MAA; 99mTc-macroaggregated albuminLatest Information Update: 28 Oct 2024
At a glance
- Originator BTG International
- Developer BTG International; Massachusetts General Hospital
- Class Albumins; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Diagnostic imaging enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Lung-cancer(Diagnosis) in USA (Intra-arterial, Injection)
- 01 Jul 2024 BTG International completes a phase-I clinical trial in Lung cancer (Diagnosis) in the USA (Intra-arterial) (NCT04105283)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Lung-cancer(Diagnosis) in United Kingdom (Intra-arterial, Injection)